Ver­i­ly scoops up a fel­low soft­ware mak­er as Amy Aber­nethy scales its clin­i­cal tri­als plat­form

Amy Aber­nethy now has a whole new set of tools to tap in­to as she scales up the clin­i­cal tri­al man­age­ment plat­form at Ver­i­ly.

The life sci­ences out­fit — now of­fi­cial­ly a sub­sidiary of Al­pha­bet on equal foot­ing with Google — has ac­quired Sig­nal­Path for an undis­closed amount, giv­ing it ac­cess to a sys­tem of dig­i­tal so­lu­tions that make it eas­i­er to run clin­i­cal tri­als, and promise to si­mul­ta­ne­ous­ly boost qual­i­ty and ef­fi­cien­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.